Financial Results - Tesla, Inc. published its press release on April 2, 2026, detailing its financial results for the period[4] Company Information - The company is listed on The Nasdaq Global Select Market under the trading symbol TSLA[2] - Tesla is classified as an emerging growth company, indicating it may have certain reporting exemptions[3]

Revenue and Sales - RUCONEST® sales accounted for approximately 85% of total revenues in 2025, with expectations for continued dominance in future revenues [38]. - Joenja® has been commercialized in the U.S., U.K., Japan, Australia, and Israel, but its market acceptance remains critical for future success [32]. - Future revenue estimates are subject to uncertainties, including market acceptance and regulatory developments [25]. - The company anticipates that 77% of its revenues in 2025 will come from two U.S. specialty pharmacies [46]. - Two U.S. customers accounted for $290.9 million, or 77%, of revenues for the year ended December 31, 2025, and $227.7 million, or 77%, for the year ended December 31, 2024 [97]. Competition and Market Dynamics - The company faces intense competition in the Hereditary Angioedema (HAE) market, with several approved products and new therapies in development [36]. - The potential for new prophylactic therapies in 2025 may reduce the demand for acute rescue medications like RUCONEST® [35]. - The development and commercialization of pharmaceuticals involve significant risks, including competition and regulatory challenges [33]. Regulatory and Compliance Issues - Regulatory approval for Joenja® in additional jurisdictions is a key focus, with plans for commercialization in those markets [19]. - The successful commercialization of products depends on adequate coverage and reimbursement from governmental authorities and health insurers [51]. - Regulatory changes, such as the introduction of Most-Favored-Nation pricing models, may lead to lower reimbursement rates for products [56]. - The company must comply with various federal and state healthcare laws, including anti-kickback statutes and false claims laws, which complicate business operations [145]. - The company faces significant penalties for non-compliance with healthcare laws, including civil and criminal penalties, which could adversely affect operations and financial results [143]. Manufacturing and Supply Chain Risks - The company relies heavily on third-party manufacturers for production, and any disruption could adversely affect sales and clinical trials [34]. - The company relies on a limited number of suppliers for essential materials, which exposes it to risks such as supply disruptions and price increases [90]. - The company has entered into manufacturing and supply agreements for Joenja® and RUCONEST® with third parties, and any interruption in supply could materially affect sales [96]. Intellectual Property and Patent Risks - The company currently holds over a hundred patent applications granted and pending in jurisdictions including the U.S., Europe, and Japan, which are crucial for protecting proprietary technology [108]. - There is uncertainty regarding the validity and enforceability of patents, which may affect the commercialization of current and future product candidates [109][112]. - The company may face litigation concerning intellectual property rights, which could result in significant liabilities and distract from business operations [111][115]. - If the company fails to obtain or maintain patent protection, it may face increased competition from generic versions of its products [114]. Financial and Economic Risks - The company is subject to significant tax risks, including potential financial loss and penalties due to changes in tax laws and practices [106][107]. - Adverse capital and credit market conditions could affect liquidity needs and the ability to finance operations [170]. - The company faces risks from general economic conditions, including inflation and supply disruptions, which could weaken demand for products [165]. Corporate Governance and Shareholder Issues - The company is subject to the Dutch Corporate Governance Code (DCGC) but does not comply with all best practice provisions, which may affect shareholder rights [195]. - Shareholders approved a proposal to exclude preemptive rights for up to 10% of issued share capital for general corporate purposes and for financing of mergers, acquisitions, and strategic alliances, each for a period of eighteen months [194]. - The company has never declared or paid dividends on its ordinary shares since listing on Euronext Amsterdam and does not anticipate paying dividends in the foreseeable future [196]. Strategic Focus and Development - Pharming Group is a global biotechnology company focused on developing therapies for rare and ultra-rare diseases with significant unmet needs [213]. - The company leverages proven clinical development and commercial infrastructure to expand its portfolio and increase access for patient communities [215]. - The company emphasizes patient insights and scientific community feedback in shaping its strategy and clinical study designs [214].

Financial Performance - Revenues for the second quarter of fiscal 2026 were $611.0 million, a 7.1% increase from the prior year, driven by a 6.8% increase in organic revenues [170]. - Net income for the second quarter was $133.1 million, an 8.1% decrease from the prior year, with diluted earnings per share (EPS) at $3.59, down 4.5% [175]. - Revenues for the six months ended February 28, 2026, increased by 7.0% to $1,206.2 million, driven by a 6.4% increase in organic revenues [191]. - Net income for the three months ended February 28, 2026, was $133,056, a decrease of 8.1% compared to the prior year [232]. - The company reported a net income of $285.6 million for the six months ended February 28, 2026, compared to $294.9 million in 2025 [274][275]. Client Metrics - Client count increased by 5.3% to 9,101, while user count rose by 10.1% to 241,352, driven mainly by corporate and wealth management clients [185]. - Annual ASV retention was over 95% as of February 28, 2026, with client retention at 91% [186]. Revenue Segmentation - Organic Annual Subscription Value (Organic ASV) totaled $2,449.1 million, reflecting a 6.7% increase over the prior year, with significant growth in the Americas [171]. - ASV from the Americas represented 66% of total ASV at $1,605.9 million, a 7.0% increase from the prior year [181]. - ASV from EMEA was $595.2 million, a 4.3% increase, while Asia Pacific ASV reached $249.1 million, a 10.0% increase [182][183]. - Americas segment revenues grew by 8.0% to $795.9 million for the six months ended February 28, 2026, primarily from workstations and data solutions [192]. - EMEA segment revenues increased by 4.0% to $298.6 million, with organic revenue growth of 4.0% and a 1.0% increase from foreign currency exchange [194]. - Asia Pacific segment revenues rose by 7.7% to $124.1 million, driven by a 9.0% increase in organic revenues [198]. Operating Expenses and Margins - Operating margin decreased to 30.3% from 32.5% in the prior year, primarily due to higher employee compensation costs [172]. - Total operating expenses for the six months ended February 28, 2026, were $841.6 million, a 10.4% increase compared to the prior year [203]. - Operating income for the six months ended February 28, 2026, increased by 0.1% to $377.0 million, with an operating margin of 30.9% [214]. - Employee compensation costs increased by 160 basis points, primarily due to higher variable compensation and annual base salaries [216]. - Cost of services as a percentage of revenues was 48.0% for the six months ended February 28, 2026, an increase of 160 basis points year-over-year [207]. - SG&A expenses as a percentage of revenues were 21.1% for the six months ended February 28, 2026, an increase of 50 basis points compared to the previous year [211]. Shareholder Returns - The company returned $204.0 million to stockholders through share repurchases and dividends during the three months ended February 28, 2026 [176]. - The company returned $385.3 million to stockholders in the form of share repurchases and dividends during the six months ended February 28, 2026 [260]. - Dividends paid during the six months ended February 28, 2026, totaled $82.4 million, compared to $78.8 million for the same period last year [264]. Cash Flow and Capital Expenditures - For the six months ended February 28, 2026, net cash provided by operating activities was $333.0 million, an increase of $72.6 million compared to $260.3 million in the same period of 2025 [274][275]. - The net cash used in investing activities for the six months ended February 28, 2026, was $21.9 million, significantly lower than $338.1 million in 2025, primarily due to reduced acquisition-related expenditures [276][277]. - Net cash used in financing activities for the six months ended February 28, 2026, was $386.7 million, compared to $45.5 million in 2025, mainly driven by $302.9 million in share repurchases [278][279]. - Free cash flow for the six months ended February 28, 2026, was $276.1 million, an increase of $65.4 million from $210.7 million in 2025 [281]. - Capital expenditures increased by 14.6% to $56.8 million for the six months ended February 28, 2026, compared to $49.6 million for the same period a year ago [265]. Acquisitions - The acquisition of LiquidityBook was completed for a purchase price of $243.2 million, net of cash acquired, on February 7, 2025 [267]. - The acquisition of Irwin was completed for a purchase price of $120.2 million, net of cash acquired, on November 5, 2024 [269]. Debt and Financing - As of February 28, 2026, outstanding debt under the 2025 Term Facility was $375.0 million, with no borrowings under the 2025 Revolving Facility [249]. - The company has a total of $1.0 billion available under the 2025 Revolving Facility, which matures on April 8, 2030 [247]. - The company has total purchase obligations with suppliers and vendors of approximately $352 million as of August 31, 2025 [271]. Taxation - The provision for income taxes increased by 14.7% for the six months ended February 28, 2026, totaling $65,588 [226]. - The effective tax rate for the six months ended February 28, 2026, was 18.7%, up from 16.2% in the prior year [229]. Other Financial Metrics - Adjusted operating income for the six months ended February 28, 2026, was $434,163, an increase of 1.8% compared to the prior year [238]. - EBITDA for the six months ended February 28, 2026, was $465,509, a 2.4% increase compared to the prior year [238]. - Adjusted diluted EPS for the six months ended February 28, 2026, was $4.46, representing a 4.2% increase from $4.28 in the same period last year [5]. - Cash and cash equivalents as of February 28, 2026, were $268.3 million, down from $337.7 million as of August 31, 2025 [242]. - The company had no off-balance sheet financing other than letters of credit as of February 28, 2026 [282]. - The company maintained foreign currency forward contracts to hedge a portion of its projected operating expenses, with maturity periods ranging from Q3 fiscal 2026 to Q2 fiscal 2027 [284]. - Non-cash charges for the six months ended February 28, 2026, were $154.2 million, primarily due to depreciation and amortization [274]. - The change in working capital for the six months ended February 28, 2026, was influenced by client collections timing and annual variable compensation payments [274].

Financial Performance - Net sales for the thirteen weeks ended February 22, 2026, were $2,787.8 million, a decrease of 1.9% compared to $2,841.0 million for the same period in 2025[8]. - Gross profit for the thirty-nine weeks ended February 22, 2026, was $1,994.3 million, down 13.2% from $2,296.3 million in the prior year[8]. - Operating profit for the thirteen weeks ended February 22, 2026, increased to $280.1 million, up 17.0% from $239.4 million in the same period last year[8]. - Net income attributable to Conagra Brands, Inc. for the thirteen weeks ended February 22, 2026, was $199.8 million, compared to $145.1 million for the same period in 2025, representing a 37.7% increase[8]. - Earnings per share (diluted) for the thirteen weeks ended February 22, 2026, was $0.42, an increase from $0.30 in the prior year[8]. - Net income for the thirty-nine weeks ended February 22, 2026, was a loss of $299.3 million, compared to a net income of $896.5 million for the same period in the previous year[16]. - The company reported a loss before income taxes of $136.6 million for the thirty-nine weeks ended February 22, 2026, primarily due to goodwill impairment charges of $771.3 million[119]. - Diluted earnings per share increased to $0.42 in Q3 fiscal 2026 from $0.30 in Q3 fiscal 2025, reflecting higher net income[132]. Assets and Liabilities - Total current assets decreased to $2,890.8 million as of February 22, 2026, from $3,071.0 million as of May 25, 2025[13]. - Total liabilities decreased to $11,048.2 million as of February 22, 2026, from $12,001.2 million as of May 25, 2025[13]. - Cash and cash equivalents were $55.1 million as of February 22, 2026, down from $68.0 million as of May 25, 2025[13]. - The carrying amount of goodwill decreased to $9,730.7 million as of February 22, 2026, primarily due to an impairment of $771.3 million in the Refrigerated & Frozen segment[52]. - Total liabilities as of February 22, 2026, were $82.2 million, with derivative liabilities at $4.4 million and deferred compensation liabilities at $77.8 million[106]. - The carrying amount of long-term debt was $7.23 billion as of February 22, 2026, with a fair value estimated at $7.16 billion[112][113]. Cash Flow - Cash flows from operating activities totaled $895.6 million, a decrease from $1,346.2 million in the prior year[16]. - The company reported a net cash flow from investing activities of $371.1 million, compared to a net outflow of $457.2 million in the previous year[16]. - Cash generated from operating activities totaled $895.6 million in the first three quarters of fiscal 2026, down from $1.35 billion in 2025, primarily due to lower operating profits[181]. - Cash generated from investing activities was $371.1 million in the first three quarters of fiscal 2026, compared to cash used of $457.2 million in the same period of fiscal 2025[182]. Impairment Charges - The company reported a goodwill impairment charge of $771.3 million for the thirty-nine weeks ended February 22, 2026[8]. - The company recognized non-cash goodwill impairment charges of $771.3 million in the Refrigerated & Frozen reporting unit, primarily due to a 150-basis point increase in the discount rate and lower projected sales and profit margins[56]. - Impairment charges of $180.0 million were recognized for the Birds Eye® brand name and $17.0 million for spreads businesses, driven by increased discount rates and lower than expected profit margins[57]. Restructuring and Costs - Conagra has approved a restructuring plan with expected costs of $357.6 million, including $113.4 million in cash charges and $244.2 million in non-cash charges, to improve SG&A expense effectiveness and optimize the supply chain by the end of fiscal 2026[37]. - In the first three quarters of fiscal 2026, Conagra recognized $10.7 million in charges related to the restructuring plan, compared to $90.7 million in the same period of fiscal 2025[37]. - The company anticipates approximately $34 million in restructuring charges related to supply chain optimization initiatives for frozen fried chicken products, with $12 million expected to be cash charges[40]. Stockholders' Equity - Stockholders' equity at February 22, 2026, totaled $8,164.1 million, a decrease from $8,915.8 million at August 24, 2025[98]. - The balance of retained earnings decreased to $5,955.6 million as of February 22, 2026, from $6,755.9 million at August 24, 2025[98]. - Dividends declared on common stock were $0.35 per share, totaling $167.7 million for the period ending February 22, 2026[98]. Segment Performance - Net sales for the thirteen weeks ended February 22, 2026, totaled $2,787.8 million, with Grocery & Snacks contributing $1,167.1 million and Refrigerated & Frozen contributing $1,133.2 million[118]. - Segment operating profit for the same period was $379.2 million, with Grocery & Snacks at $216.7 million and Refrigerated & Frozen at $104.8 million[118]. - Segment SG&A expenses for the thirteen weeks ended February 22, 2026, totaled $280.3 million, with the highest expenses in Grocery & Snacks at $113.0 million[118]. - The Grocery & Snacks segment saw a 6.3% decline in net sales to $1.17 billion, while the Refrigerated & Frozen segment increased by 1.6% to $1.13 billion[146]. Tax and Litigation - The effective tax rate for the third quarter of fiscal 2026 was 13.0%, down from 23.3% in the same quarter of fiscal 2025[76]. - The Company has settled litigation matters for a total of $141.1 million in fiscal 2026 and $25 million in fiscal 2025, with an additional $44.3 million expected to be paid in fiscal 2026 and Q1 fiscal 2027[82]. - As of February 22, 2026, the accrual for all litigation matters was $47.8 million[87]. Future Outlook - The company anticipates ongoing challenges related to supply chain disruptions and inflation impacting future performance[127]. - Conagra Brands anticipates continued volatility in costs of goods sold due to inflation and trade policy changes in fiscal 2026[134].

Financial Performance - Net income for the three months ended February 28, 2026, was $1,116 million, a decrease of 40% compared to $1,854 million for the same period in 2025[16]. - Basic earnings per share for the quarter ended February 28, 2026, was $0.13, down from $0.21 for the quarter ended March 1, 2025[51]. - Total sales revenue for the three months ended February 28, 2026 decreased by $1,822 or 2.2% compared to the prior year, primarily due to winter weather disruptions[80]. - Consolidated net sales of furniture and accessories for the quarter ended February 28, 2026, were $80,340 million, compared to $82,162 million for the quarter ended March 1, 2025[60]. - Retail sales from Company-owned stores decreased by $749 or 1.4%, while sales to external wholesale customers decreased by $1,073 or 3.7%[80]. - Wholesale net sales for the three months ended February 28, 2026 increased by $34 or 0.1%, with a 0.6% increase in shipments to the retail store network[92]. - Gross margins for the three months ended February 28, 2026 decreased by 80 basis points, attributed to lower margins in both wholesale and retail businesses[81]. - Gross margin for the same period declined by 170 basis points, attributed to lower margins on in-line goods due to delayed price increases related to tariff costs[95]. - SG&A expenses as a percentage of sales increased by 70 basis points from the previous year, reflecting reduced leverage of fixed costs due to lower sales levels[81]. Assets and Liabilities - Total assets decreased to $316,154 million as of February 28, 2026, down from $323,819 million on November 29, 2025, representing a decline of approximately 2.05%[14]. - Total current liabilities decreased to $71,823 million as of February 28, 2026, down from $76,984 million, a reduction of about 6.7%[14]. - Cash and cash equivalents decreased to $32,989 million from $41,277 million, reflecting a decline of approximately 20%[16]. - Accounts receivable increased to $15,125 million gross, with a net of $14,662 million after accounting for an allowance for credit losses of $463 million[30]. - Total inventories as of February 28, 2026, were $65,666 million, an increase from $61,790 million as of November 29, 2025[33]. - The company had a line of credit of up to $25,000 million, with $5,866 million outstanding under standby letters of credit as of February 28, 2026[38]. - The liability for the Supplemental Retirement Income Plan was $5,617 million as of February 28, 2026, compared to $5,611 million on November 29, 2025[39]. - Total post-employment benefit obligations increased to $11,629 million as of February 28, 2026, from $11,379 million on November 29, 2025[45]. - The company maintained a Consolidated Minimum Tangible Net Worth of at least $120,000 million, in compliance with its credit facility requirements[38]. Cash Flow and Operating Activities - Net cash used in operating activities was $5,468 million for the three months ended February 28, 2026, compared to a net cash used of $52 million in the same period of 2025[16]. - The overall cash position declined by $8,288 during the first three months of 2026, with cash and cash equivalents totaling $50,952 as of February 28, 2026[107]. - Interest income for the three months ended February 28, 2026, was $553 million, a decrease of $6 million from the prior year[102]. - Other loss, net, for the same period was $192 million, a decline of $267 million from the prior year, primarily due to lower costs associated with company-owned life insurance[103]. Tax and Expenses - The effective tax rate for the three months ended February 28, 2026, was 26.5%, compared to 27.4% for the same period in 2025[24]. - The effective tax rate for the quarter was 26.5%, compared to 27.4% in the prior year, influenced by state income taxes and permanent differences[105]. - The company recognized an expense of $12 million under deferred compensation arrangements during the three months ended February 28, 2026[46]. - New store pre-opening costs incurred during the quarter amounted to $95 million, with total start-up losses expected to range from $400 million to $600 million per store[96][98]. E-commerce and Sales Trends - E-commerce revenue saw a 25% increase in web sales for fiscal 2025, with written sales orders for the web increasing by 28% for the quarter and delivered sales increasing by 46%[76]. - Approximately 60% of wholesale sales arise from the network of 86 Company-owned and licensee-owned Bassett Home Furnishings stores[73]. - Over 75% of wholesale revenues are derived from products manufactured in the United States, utilizing a mix of domestic and globally sourced components[78]. - Wholesale backlog at February 28, 2026 was $16,745, down from $19,519 at November 29, 2025 and $19,515 at March 1, 2025[93]. Legal and Compliance - The company is involved in various legal and environmental matters, but these are not expected to have a material adverse effect on financial position or future results[114].

Financial Performance - NIKE, Inc. revenues for Q3 fiscal 2026 were $11.3 billion, flat on a reported basis and down 3% on a currency-neutral basis[91]. - Net income for Q3 fiscal 2026 was $520 million, a decrease of 35% compared to $794 million in Q3 fiscal 2025[101]. - Total NIKE, Inc. EBIT decreased by 23% to $635 million for the three months ended February 28, 2026, compared to $826 million in the same period of 2025[123]. - Total revenues for NIKE, Inc. were $11,279 million for the three months ended February 28, 2026, a slight increase of 0% compared to $11,269 million in the same period of 2025[123]. - Total revenues for the nine months ended February 28, 2026, decreased by 11% to $4,550 million compared to $5,110 million in the same period of 2025[132]. Revenue Breakdown - NIKE Brand wholesale revenues increased to $6.5 billion in Q3 fiscal 2026, up from $6.2 billion in Q3 fiscal 2025, driven by higher revenues in North America and Asia Pacific & Latin America[91]. - NIKE Direct revenues decreased to $4.5 billion in Q3 fiscal 2026 from $4.7 billion in Q3 fiscal 2025, primarily due to a decrease in traffic[91]. - NIKE Brand revenues for the first nine months of FY2026 were $35.4 billion, up 1% on a reported basis, with a currency-neutral decrease of 1%[106]. - NIKE Brand wholesale revenues for the first nine months of FY2026 were $20.8 billion, up 7% on a reported basis and up 5% on a currency-neutral basis[106]. Cost and Margin Analysis - Gross margin for Q3 fiscal 2026 decreased by 130 basis points to 40.2%, mainly due to higher tariffs in North America[91]. - Gross profit for Q3 FY2026 was $4.53 billion, a 3% decrease from $4.68 billion in Q3 FY2025, resulting in a gross margin of 40.2%, down 130 basis points year-over-year[107][108]. - Gross margin contracted by 350 basis points to 39.6% due to higher tariffs, partially offset by higher ASP and lower inventory obsolescence reserves[127]. - Gross margin for Converse contracted by approximately 970 basis points, primarily due to brand reset costs and higher inventory obsolescence reserves[148]. Tax and Expenses - The effective tax rate for Q3 fiscal 2026 was 20.0%, compared to 5.9% in Q3 fiscal 2025[101]. - Total selling and administrative expenses for Q3 FY2026 were $3.98 billion, up 2% from $3.89 billion in Q3 FY2025, representing 35.3% of revenues[108]. - Demand creation expense increased by 4% to $416 million, attributed to higher sports marketing expenses[127]. - Demand creation expense increased by 11%, primarily due to unfavorable foreign currency exchange rates and higher sports marketing expenses[131]. Shareholder Returns and Capital Management - NIKE returned approximately $609 million to shareholders through dividends in Q3 fiscal 2026[91]. - The company repurchased a total of 1.8 million shares for $122.4 million under the $18 billion share repurchase program, with 124.4 million shares repurchased at a cost of approximately $12.1 billion as of February 28, 2026[163]. - Cash provided by operations was $1,231 million, a decrease from $3,235 million in the same period of 2025[159]. - Cash used by financing activities for the nine months ended February 28, 2026, was $1,778 million, primarily driven by dividend payments, compared to $4,176 million in 2025[162]. Market and Geographic Performance - North America revenues increased by 3% on a currency-neutral basis, with wholesale revenues up 11%, while NIKE Direct revenues decreased by 5%[127]. - EMEA revenues decreased by 7% on a currency-neutral basis, with NIKE Direct revenues down 13% due to a 6% decline in digital sales and a 20% decline in store sales[131]. - Greater China revenues decreased by 10% on a currency-neutral basis, with wholesale revenues down 13% and NIKE Direct revenues down 5%[135]. - APLA revenues decreased 2% on a currency-neutral basis, with NIKE Direct revenues down 8% due to a 12% decline in digital sales and a 3% decline in store sales[140]. Operational Challenges - The company recognized pre-tax charges of $230 million for the three months ended February 28, 2026, primarily related to employee severance costs[94]. - The U.S. Supreme Court ruled that tariffs imposed under the IEEPA were unauthorized, with total tariffs paid amounting to approximately $1.0 billion[95]. - Other (income) expense, net for Q3 FY2026 was $82 million, an increase from $38 million in Q3 FY2025, mainly due to settlements of legal matters[115][116]. - Corporate expenses decreased by 13% to $411 million for the three months ended February 28, 2026, compared to $470 million in the same period of 2025[123].

Market Influence and Operations - The Coca-Cola Company significantly influences the company's operations, with 28% and 29% of net sales generated in Brazil for 2024 and 2025, respectively, and 25% and 22% in Argentina[52]. - Operations in Chile represented 42.4% of the company's assets and 38.6% of net sales for 2024, indicating significant reliance on the Chilean economy[99]. - Operations in Brazil accounted for 29.0% of assets and 28.2% of net sales for 2024, highlighting the importance of Brazilian economic conditions[110]. - The company’s operations in Argentina represented 24.8% and 22.2% of net sales for 2024 and 2025, respectively[139]. Economic and Currency Risks - A devaluation of local currencies against the Chilean peso could negatively impact the company's financial results, as a significant portion of revenues is generated in foreign currencies[52]. - The Brazilian real appreciated 8% in 2023, depreciated 22% in 2024, and appreciated 13% in 2025 against the U.S. dollar[136]. - In Argentina, the peso depreciated 78% in 2023, 22% in 2024, and 29% in 2025 against the U.S. dollar[146]. - Inflation in Chile could increase operational costs and reduce demand for products, as many supply contracts are indexed to the consumer price index[109]. - Inflationary pressures in Brazil may increase costs and reduce profit margins, affecting overall financial performance[135]. - Argentina is classified as a hyperinflationary economy under IAS 29 due to a cumulative three-year inflation rate exceeding 100%[150]. - The application of IAS 29 has resulted in the need to restate non-monetary assets and liabilities, impacting reported results and net earnings[150]. Regulatory and Compliance Challenges - The company faces increasing environmental regulations that may raise operating costs and affect consumer demand, particularly regarding plastic packaging[47]. - The company must navigate complex local regulations across its operating territories, which could increase compliance costs and affect financial performance[45]. - The company is subject to additional labeling and warning requirements that may inhibit product sales and affect overall financial results[58]. - The company is subject to legal proceedings related to monopolistic practices, which could lead to significant liabilities and operational changes[90]. Competitive Landscape - The beverage business is highly competitive, with local and regional brands posing significant price competition, which could adversely affect net profits and margins[51]. - Increased public health concerns regarding sugar-sweetened beverages may lead to reduced demand and additional regulatory pressures[50]. Supply Chain and Operational Risks - Raw material costs, including concentrate, sweeteners, and packaging materials, are subject to market volatility and currency exchange risks, which may affect profitability[53]. - Water scarcity and poor water quality are significant concerns, as they may lead to increased production costs and capacity constraints, potentially affecting profitability[59]. - The company faces risks from instability in the supply of utility services and fluctuations in oil prices, which could materially impact operational costs and financial performance[56]. - The company is exposed to risks from pandemics, which could limit business activities and disrupt raw material supply chains, potentially affecting financial performance[75]. Strategic and Expansion Challenges - The company may face challenges in successfully implementing expansion strategies and achieving expected operational efficiencies from acquisitions, which could adversely affect financial results[71]. - Labor unrest and the inability to renew collective bargaining agreements on satisfactory terms could lead to work stoppages, impacting operations and net revenues[87]. - The company may struggle to recruit or retain key personnel, which could disrupt business operations and negatively impact financial performance[96]. Tax and Financial Liabilities - RJR is involved in tax proceedings with Brazilian federal tax authorities, with claims totaling approximately R$3,625 million related to value-added tax on industrialized products[127]. - The aggregate amount involved in various judicial proceedings for RJR currently amounts to approximately R$7,900 million[127]. - RJR is currently awaiting formal notification of tax debts cancellation, expected during 2026, which involves R$445 million related to the years 2017 and 2018[129]. - The Brazilian government approved a tax reform in late 2023 aimed at simplifying consumption taxes, which may impact the company's tax burden and profitability[115]. - The new tax regime in Brazil will transition from January 2026 to December 2032, reorganizing existing consumption taxes into new categories[117]. Environmental, Social, and Governance (ESG) Concerns - Increased scrutiny from stakeholders regarding environmental, social, and governance (ESG) matters could impact the company's reputation and ability to sell products if ESG goals are not met[64]. - Climate change poses risks to agricultural productivity, which could increase the costs of key ingredients like sugarcane and corn, adversely impacting the company's operations[63]. Recent Developments and Acquisitions - The merger with Embotelladoras Coca-Cola Polar S.A. in 2012 granted former shareholders of Polar a 19.68% ownership interest in the merged entity, enhancing Coca-Cola Andina's market position in South America[193]. - In 2018, Coca-Cola Andina completed the acquisition of 100% of the shares of Comercializadora Novaverde S.A., a company focused on the production and distribution of juices and ice cream[196]. - In September 2021, Andina Brazil acquired 50% of the Therezópolis beer brands for R$35 million, expanding its beverage portfolio in Brazil[214]. - In April 2022, the Coca-Cola Brazil System signed a Master Agreement with Campari for the exclusive distribution of Campari-branded beverages throughout Brazil, with an expiration date of December 31, 2026[215]. - In August 2023, Andina Brazil signed a Distribution Agreement with Perfetti Van Melle for the distribution of its branded portfolio throughout Brazil, authorized by a Master Agreement signed in July 2022[216]. - The restructuring of the juice and mate herb business in Brazil resulted in Andina Brazil holding a 10.87% ownership interest in Leão Alimentos y Bebidas Ltda.[207].

Market Conditions - As of March 23, 2026, the Baltic Dry Index (BDI) stood at 2,037, up 23.3% from one year ago, indicating improved dry bulk market conditions [36]. - The average one-year time charter rate for an eco-efficient MR tanker was $33,000/day as of mid-March 2026, an increase of nearly $10,000 from early January 2026 [37]. - The product tanker sector has experienced robust market conditions from 2022 through 2024 due to disruptions in trade routes caused by geopolitical conflicts [37]. - The demand for oceangoing vessels is influenced by global economic growth, seasonal demand changes, and the capacity of the global dry bulk and tanker fleets [41]. - An oversupply of product tanker and dry-bulk capacity could lead to reductions in charter rates and vessel values, negatively impacting profitability [51]. - The global dry bulk fleet has significantly increased over the past 10 years, with newbuilding orders substantially rising in 2023 and 2024, potentially leading to declining charter rates if demand does not keep pace [53]. Economic Risks - An economic slowdown or changes in the Asia Pacific region could materially adversely affect the company’s business and financial condition [28]. - The Chinese dry bulk imports have accounted for the majority of global dry bulk transportation growth annually over the last decade, making the company's financial condition sensitive to economic downturns in China [47]. - The IMF forecasts a decline in China's GDP growth from 5.0% in 2025 to 4.5% in 2026 and 4.0% in 2027, which may adversely affect demand for shipping services [55]. - Economic slowdown in the Asia Pacific region, especially in China, may significantly affect the company's operations due to reliance on dry-bulk commodity transport [67]. Operational Risks - The company operates in a highly competitive international market, with a substantial portion of revenues derived from a limited number of customers, increasing the risk of revenue loss [32]. - The company’s revenues are significantly affected by seasonal, cyclical, and volatile charter hire rates in the product tanker and dry-bulk sectors [36]. - The company is exposed to international operational risks that may reduce revenue or increase expenses due to global operations [34]. - The company faces risks from rising inflation, interest rates, and supply chain constraints that could negatively impact financial results [28]. - The company may incur higher crew wages of over $4,000 per day for vessels operating in war zones, impacting operational costs [33]. - Labor interruptions could have a material adverse effect on the company's business, particularly due to the employment of crew members from regions experiencing hostilities [176]. Geopolitical Risks - The company faces risks from geopolitical issues, including conflicts in the Middle East and trade tensions, which could disrupt international shipping and affect financial performance [58]. - The ongoing Ukraine War has led to multiple rounds of sanctions against Russia, which may adversely impact the company's business due to Russia's role as a major exporter of crude oil and natural gas [61]. - The U.S. has imposed sanctions on Russian energy products, including crude oil and natural gas, which may adversely affect the company's operations [62]. - Trade tariffs and economic sanctions could limit trading activities, particularly between the U.S. and countries in the Middle East and Asia, impacting the company's financial condition [64]. - The Ukraine War has led to significant sanctions affecting maritime transportation of Russian oil, limiting operational scope and potential contractual disputes [75]. Environmental Regulations - The International Maritime Organization (IMO) aims to reduce total annual greenhouse gas emissions from international shipping by at least 20% by 2030, striving for 30%, compared to 2008 levels [1]. - The IMO's revised strategy adopted in July 2023 includes a commitment to reach net-zero greenhouse gas emissions from international shipping around or close to 2050 [1]. - Compliance with the IMO's sulfur emissions regulation, effective January 1, 2020, may lead to increased costs for ship owners, including the use of 0.5% sulfur fuels or installation of scrubbers [2]. - The European Union's Emissions Trading Scheme (ETS) for ships will require 40% of allowances to be surrendered in 2025 for the year 2024, increasing to 100% by 2027 for the year 2026 [4]. - The Fuel EU Maritime Regulation mandates a 2% reduction in greenhouse gas intensity of fuel used by covered vessels starting January 1, 2025, with further reductions planned every five years [5]. - The company faces significant compliance costs related to new emission controls and greenhouse gas emissions management programs [6]. Financial Condition - The company’s fleet has a weighted average age of 10.8 years, which may affect competitiveness against newer, more efficient vessels [6]. - The company currently has no vessels on order, but plans to purchase additional vessels as part of growth and fleet renewal plans [154]. - The company may experience difficulties obtaining financing due to tighter lending standards and increased capital requirements in the shipping industry [135]. - The company may issue additional shares of common stock in the future for vessel acquisitions or debt repayment, which could negatively impact the market price of existing shares [202]. - The company does not intend to pay cash dividends on common stock in the near future, with future payments subject to board discretion and compliance with legal requirements [213]. - The company is required to maintain minimum liquidity cash balances of $1.35 million for each vessel borrower as of December 31, 2024 and 2025 [190]. Insurance and Liability - The company carries hull and machinery, protection and indemnity, and war risk insurance on each vessel, but faces risks regarding insurance coverage [169]. - The company does not carry insurance covering the loss of revenues resulting from vessel off-hire time [169]. - The company maintains pollution liability coverage insurance of $1.0 billion per incident for each vessel in its fleet, but catastrophic events could exceed this coverage [171]. - The company may face increased premium payments for insurance based on its claim records, which could result in significant expenses [172]. Corporate Governance - Maritime Investors Corp, controlled by the CEO, owns 58.5% of the total outstanding common stock, potentially limiting other shareholders' influence [166]. - The company’s corporate governance practices are exempt from certain Nasdaq requirements, potentially affecting stockholder protections [220]. - Anti-takeover provisions in the company's Articles of Incorporation and Bylaws may hinder stockholders from replacing the Board of Directors or discourage acquisitions [222].

Competition and Market Dynamics - The company faces significant competition in the provision of educational services, which may adversely affect market share and profitability [44]. - Increased competition in the graduate program landscape may result in pricing pressure and longer sales cycles, negatively impacting revenue [49]. - Changes in government investment strategies in education could increase competition, particularly if public institutions expand and enhance their offerings [64]. - The company’s revenues are highly concentrated in tuition fees for medical courses, making it vulnerable to adverse economic or regulatory factors affecting demand [44]. - The evolving regulatory framework for medical education in Brazil remains uncertain, affecting the authorization of new medical programs and student seats [50]. Economic and Regulatory Environment - Economic uncertainty and political instability in Brazil could harm the company's business and the price of its Class A common shares [47]. - The Brazilian government has significant influence over the economy, and changes in policies or regulations could impact the company's operations [43]. - Recent regulatory changes may create competitive disparities, allowing certain institutions to expand more rapidly or at lower costs than those subject to federal oversight [54]. - Proposed tax reforms, including the introduction of the Goods and Services Tax (IBS) and the Social Contribution on Goods and Services (CBS), may significantly impact the company's tax burden and financial performance [70][72]. - The company is subject to supervision by the Ministry of Education (MEC), which may impose sanctions for non-compliance with regulatory requirements [106]. Financial Performance and Risks - The company may require additional funds to support its expansion strategy, and failure to secure financing could adversely affect growth plans [44]. - The allowance for expected credit losses as a percentage of revenue was 2.6% for the year ended December 31, 2023, indicating potential risks in cash flow due to payment delinquencies [176]. - The company’s ability to collect accounts receivable may be impacted by economic conditions, leading to increased payment defaults and affecting overall financial health [176]. - The company is dependent on the performance of its subsidiaries for dividend distributions, which may be adversely affected if those subsidiaries do not perform positively [186]. - The company approved the distribution of accumulated profit reserves from Brazilian subsidiaries, with payments expected through 2028, to mitigate potential tax burdens from new legislation [188]. Operational Challenges - The company operates a large number of campuses and facilities across multiple regions in Brazil, which presents ongoing operational challenges related to maintenance and safety [88]. - The company is experiencing significant operational expansion, facing challenges in talent acquisition and retention, cash flow management, and internal controls, which could adversely affect financial performance [145]. - The integration of acquired companies poses operational risks that could adversely affect the company’s strategic objectives and financial results [172]. - Ongoing construction and renovation projects require additional licenses, and failure to obtain these could result in delays and increased costs, adversely affecting financial performance [140]. - The company faces risks related to occupational health and safety, which could lead to regulatory consequences and financial liabilities [215]. Compliance and Legal Risks - The company is subject to anti-corruption, anti-bribery, and anti-money laundering laws, which impose significant compliance obligations and risks of liability for violations [94]. - The company is subject to strict consumer protection laws, which could result in penalties and legal proceedings that may harm its reputation and financial condition [132]. - Non-compliance with health and safety standards can result in serious consequences, including potential death or physical injury to individuals on the premises [87]. - The company is required to comply with the Economic Substance Act in the Cayman Islands, which may create significant additional costs and operational impacts [100]. - Regulatory compliance risks related to healthcare and digital health regulations could limit product offerings and increase operational costs [171]. Technology and Innovation - The company must continually update its educational content and digital products to remain competitive, particularly in response to rapid technological changes like artificial intelligence [57]. - The company must continuously update its technology and systems to remain competitive, which is time-intensive and may lead to higher future costs [150]. - Compliance with evolving AI regulations in Brazil may lead to higher operational costs and delays in innovation [229]. - The company’s success in distance learning depends on affordable internet access and the ability to adapt to rapidly changing technologies [221]. - Cybersecurity threats pose significant risks, and a breach could lead to reputational damage and financial losses [154]. Strategic Initiatives and Goals - The company aims to expand operations by acquiring medical higher education institutions and health tech companies, but faces challenges in identifying and integrating suitable acquisitions [44]. - The company is focused on acquiring medical higher education institutions and health tech companies, but faces risks in identifying suitable targets and integrating them effectively [151]. - The integration of acquired companies is ongoing, with all but one (Medical Harbour) fully integrated, and successful integration is crucial for realizing anticipated benefits [153]. - The company aims to achieve gender equity by having women occupy half of managerial positions by 2030 and plans to deliver an additional five million free healthcare consultations by 2030 [148]. - The company’s organic growth strategy includes opening new campuses, which requires substantial investments and poses challenges in maintaining quality standards [178].

Operations and Capacity - The company operates a manufacturing facility of 13,500 square feet, currently at approximately 15% to 20% capacity, with the potential to produce approximately 1.4 billion square inches of product annually at full capacity[19]. - The company maintains a combined corporate office and manufacturing facility in Langhorne, Pennsylvania, leasing approximately 16,500 square feet, with the lease expiring on January 31, 2031[49]. - The company has expanded its business model to include branded consumer products and custom gel opportunities since 2020[174]. Joint Ventures and Partnerships - In May 2023, the company formed a joint venture with CG Laboratories, Inc., owning a 50% interest in CG Converting and Packaging, LLC, to enhance its ability to deliver finished goods[16]. - The company has a joint venture with CG Laboratories, Inc., called CG Converting and Packaging, LLC, which allows it to expand its ability to deliver finished goods to its growing customer base[121]. - The company aims to pursue strategic partnerships to expand its business, but may face challenges in identifying and completing favorable partnerships[80]. Product Development and Innovation - The company has successfully utilized over 200 active ingredient combinations in its hydrogels, which are marketed for various applications including drug delivery and wound care[19]. - The company is developing new products targeting the OTC pharmaceutical drug delivery market, pain management, and cosmetics, among others[22]. - The NEXDrape device, designed for patients with impaired skin, is currently undergoing proof of concept studies and aims to provide a gentler alternative to traditional adhesive surgical drapes[25][26]. - The company plans to file a 510(k) premarket submission with the FDA for both NEXDrape and NEXDerm, an adhesive tape for securing medical devices[26][27]. - Research and development expenses are focused on new product development, with costs expensed as incurred[194]. Financial Performance - Revenues for the year ended December 31, 2025, were $11,421 thousand, an increase of $2,733 thousand or 31.5% compared to $8,688 thousand in 2024[130]. - Gross profit for 2025 was $4,509 thousand, up $1,761 thousand from $2,748 thousand in 2024, with a gross profit margin of approximately 39.5% compared to 31.6% in 2024[132]. - Selling, general and administrative expenses rose by $1,635 thousand or 26.3% to $7,859 thousand in 2025, driven by increases in compensation, advertising, and professional fees[133]. - Net loss attributable to NexGel stockholders improved to $3,000,000 in 2025 from $3,281,000 in 2024, a reduction of 8.6%[167]. - The company expects to continue incurring losses in the near term, raising concerns about its ability to operate as a going concern without additional capital[144]. Market and Competition - The company faces competition from established players like Johnson & Johnson and Procter & Gamble, necessitating strategic partnerships for success in the medical device sector[32]. - The company faces intense competition in the hydrogel manufacturing industry, with no assurance of developing products that achieve greater market acceptance than competitors[63]. - The company’s future success depends on market acceptance of its existing and future products by the medical community and end-users[55]. Regulatory and Compliance - The company is currently registered as a device manufacturer and distributor with the FDA and intends to register as a drug facility when required[42]. - The company is subject to extensive governmental regulations, which can lead to fines, product recalls, and delays in new product approvals[70]. - The company is subject to various environmental regulations and has made significant investments to comply, but future costs are unpredictable[43]. Employee and Corporate Governance - The company recognizes the importance of its employees as a key asset in achieving strategic goals and is focused on developing a high-performance culture[48]. - The company’s principal stockholders, officers, and directors own approximately 16.3% of its stock, potentially influencing decisions that may not align with other shareholders' interests[87]. Risks and Challenges - The company has identified material weaknesses in its internal control over financial reporting, which could lead to errors in financial statements[88]. - The company may face significant product liability claims, which could incur substantial expenses and harm its reputation[75]. - The company has limited sales, marketing, and distribution capabilities, which may adversely affect its financial condition if not addressed[74]. - The company is reliant on two manufacturers for key ingredients in its hydrogels, which poses risks of supply interruptions and increased costs[76]. Shareholder Information - The company has over 983 shareholders of record and 8,163,458 shares of common stock outstanding as of March 31, 2026[114]. - The company has issued 907,111 shares of common stock upon the exercise of outstanding stock options at a weighted average exercise price of $2.94 per share, and 5,142,940 shares upon the exercise of warrants at a weighted average exercise price of approximately $5.11 per share[97]. Revenue Recognition and Accounting - The company recognizes revenue primarily from contract manufacturing, custom and white label finished goods, and branded consumer products, with revenue recognized upon shipment to customers[212]. - The company continues to monitor marketplace changes to adjust return estimates appropriately, indicating proactive risk management[214].